Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tempest Therapeutics Inc.

www.tempesttx.com

Latest From Tempest Therapeutics Inc.

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing

Finance Watch: Hua Medicine Raises $117.4m While Evaluating A Hong Kong IPO

Hua, already considering an IPO in Hong Kong for up to $400m, closed concurrent VC rounds that will fund its late-stage diabetes program in China, but it may still need to go public to enter other markets. Also, Heron raised cash for its next commercial product, among other public company financings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Tempest Therapeutics Inc.
  • Senior Management
  • Tom Dubensky, Jr., PhD, CEO
    Alicia Levey, PhD, VP, Bus. Dev. & Strategy
    Ginna Laport, MD, CMO
    Stephen Brady, Pres. & COO
  • Contact Info
  • Tempest Therapeutics Inc.
    One Sansome St.
    Ste. 3690
    San Francisco, CA 94104
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register